首页> 外文期刊>Hematological oncology >Plasmablastic haemato-lymphoid neoplasm with a complex genetic signature of Burkitt lymphoma responding to bortezomib
【24h】

Plasmablastic haemato-lymphoid neoplasm with a complex genetic signature of Burkitt lymphoma responding to bortezomib

机译:响应于硼替佐米的具有伯基特淋巴瘤复杂基因特征的成纤维细胞血细胞淋巴瘤

获取原文
获取原文并翻译 | 示例
           

摘要

Plasmablastic lymphoma shares many morphologic features with plasmablastic plasma cell myeloma. The activation of MYC oncogene in these lymphomas may be an important pathogenetic element associated with Epstein-Barr virus infection. We describe herein an elderly man with a plasmablastic lymphoid neoplasm displaying unique morphologic, cytogenetic and clinical features. This case might offer additional insights to the complex but fascinating topic of hybrid haemato-lymphoid neoplasms such as plasmablastic lymphoma-myeloma. In addition, the patient responded to the treatment with bortezomib. Newer antimyeloma agents such as bortezomib have shown promise in the treatment of these neoplasms and should further be explored for their therapy.
机译:浆母细胞性淋巴瘤与浆母细胞浆细胞骨髓瘤具有许多形态学特征。这些淋巴瘤中MYC癌基因的激活可能是与爱泼斯坦-巴尔病毒感染相关的重要致病因素。我们在这里描述了一位老人,患有浆母细胞淋巴样肿瘤,表现出独特的形态,细胞遗传学和临床特征。这种情况可能为杂种血细胞淋巴瘤(例如浆母细胞淋巴瘤-骨髓瘤)这一复杂但引人入胜的话题提供更多见解。另外,患者对硼替佐米的治疗有反应。新型抗骨髓瘤药物如硼替佐米已在这些肿瘤的治疗中显示出希望,应进一步探索其治疗方法。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号